BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 21923688)

  • 1. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
    Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
    Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
    Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
    J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
    Lee BH; Kim N; Hwang TJ; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Helicobacter; 2010 Feb; 15(1):38-45. PubMed ID: 20302588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
    Chung JW; Lee JH; Jung HY; Yun SC; Oh TH; Choi KD; Song HJ; Lee GH; Kim JH
    Helicobacter; 2011 Aug; 16(4):289-94. PubMed ID: 21762268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
    Wang Z; Wu S
    Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
    Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C
    Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
    Matsuhisa T; Kawai T; Masaoka T; Suzuki H; Ito M; Kawamura Y; Tokunaga K; Suzuki M; Mine T; Takahashi S; Sakaki N
    Helicobacter; 2006 Jun; 11(3):152-8. PubMed ID: 16684262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
    Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
    Helicobacter; 2006 Feb; 11(1):46-51. PubMed ID: 16423089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
    Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection.
    Minakari M; Davarpanah Jazi AH; Shavakhi A; Moghareabed N; Fatahi F
    Helicobacter; 2010 Apr; 15(2):154-9. PubMed ID: 20402818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
    Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
    Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
    Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
    Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.